Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 117
Filter
1.
Hum Exp Toxicol ; 35(7): 767-74, 2016 Jul.
Article in English | MEDLINE | ID: mdl-26351291

ABSTRACT

Venlafaxine is commonly used in the United States for approved and non-Food and Drug Administration-approved indications in adults. It is used off-label to treat children for psychiatric diagnoses. The aim of the study was to describe venlafaxine toxicities in children and to identify the venlafaxine dose per weight that correlates with toxicities. An 11-year retrospective study of venlafaxine ingestion in children was performed using the California Poison Control System (CPCS) database. Data was extracted from phone calls received by CPCS clinicians and follow-up phone calls made to assess the patient's progress in a health-care setting. Inclusion criteria were venlafaxine ingestion cases reported to CPCS between January 2001 and December 2011, children aged 20 years and under, venlafaxine as the only ingested substance, managed in a health-care facility, and followed to a known outcome. Two hundred sixty-two cases met the study criteria. Common presentations included gastrointestinal (14.9%), altered mental status (13.7%), and tachycardia (13.4%). The majority of the cases resulted in no effect (51.5%) or minor effect (19.9%). The average estimated dose per weight was 18.3 mg/kg in all patients and 64.5 mg/kg in those experiencing moderate-to-severe adverse effects. Seizures occurred in only 4 of the 262 cases at doses ranging from 1500 to 7500 mg. Although the estimated dose per weight exceeded 10 mg/kg for the majority of the cases, only 12 cases resulted in moderate or severe outcomes. The majority of venlafaxine ingestion cases in children resulted in either no clinical effects or minor clinical effects.


Subject(s)
Drug Utilization Review/statistics & numerical data , Drug-Related Side Effects and Adverse Reactions/epidemiology , Poison Control Centers/statistics & numerical data , Serotonin and Noradrenaline Reuptake Inhibitors/toxicity , Venlafaxine Hydrochloride/toxicity , Adolescent , California , Child , Child, Preschool , Dose-Response Relationship, Drug , Drug-Related Side Effects and Adverse Reactions/etiology , Female , Humans , Infant , Male , Off-Label Use/statistics & numerical data , Retrospective Studies , Serotonin and Noradrenaline Reuptake Inhibitors/administration & dosage , Serotonin and Noradrenaline Reuptake Inhibitors/therapeutic use , Venlafaxine Hydrochloride/administration & dosage , Venlafaxine Hydrochloride/therapeutic use , Young Adult
2.
Acta Psychiatr Scand ; 113(2): 135-41, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16423165

ABSTRACT

OBJECTIVE: To determine whether atypical antipsychotic polytherapy is a risk factor for drug treatment for extrapyramidal side-effects (anti-EPS drugs) and whether the risk is attributable to antipsychotic dose. METHOD: We studied Iowa Medicaid beneficiaries aged 18-64 years with an active atypical and no conventional antipsychotic on January 1, 2001. The association of atypical antipsychotic polytherapy with anti-EPS drug treatment was determined. Multiple logistic regression was utilized to adjust for covariates in two models, the first adjusting for age, sex and the specific antipsychotic(s) prescribed, and the second also adjusting for doses. RESULTS: Among 4400 patients, the unadjusted odds of anti-EPS treatment were increased two-fold with polytherapy. Polytherapy remained a risk factor in the first model (OR 1.5, 95% CI 1.1-2.0), but not after adjusting for doses (OR 1.0, 95% CI 0.7-1.4). CONCLUSION: Atypical antipsychotic polytherapy is a risk factor for anti-EPS drug treatment, apparently because of higher cumulative doses.


Subject(s)
Antipsychotic Agents/adverse effects , Basal Ganglia Diseases/chemically induced , Psychotic Disorders/drug therapy , Adolescent , Adult , Antipsychotic Agents/administration & dosage , Basal Ganglia Diseases/diagnosis , Basal Ganglia Diseases/epidemiology , Benzodiazepines/administration & dosage , Benzodiazepines/adverse effects , Clozapine/administration & dosage , Clozapine/adverse effects , Cross-Sectional Studies , Delayed-Action Preparations , Dibenzothiazepines/administration & dosage , Dibenzothiazepines/adverse effects , Drug Therapy, Combination , Female , Humans , Iowa , Male , Mathematical Computing , Medicaid , Middle Aged , Models, Statistical , Olanzapine , Product Surveillance, Postmarketing , Psychotic Disorders/epidemiology , Quetiapine Fumarate , Regression Analysis , Risk Factors , Risperidone/administration & dosage , Risperidone/adverse effects , Statistics as Topic
3.
Br J Cancer ; 86(5): 774-8, 2002 Mar 04.
Article in English | MEDLINE | ID: mdl-11875742

ABSTRACT

Resveratrol is a cancer preventative agent that is found in red wine. Piceatannol is a closely related stilbene that has antileukaemic activity and is also a tyrosine kinase inhibitor. Piceatannol differs from resveratrol by having an additional aromatic hydroxy group. The enzyme CYP1B1 is overexpressed in a wide variety of human tumours and catalyses aromatic hydroxylation reactions. We report here that the cancer preventative agent resveratrol undergoes metabolism by the cytochrome P450 enzyme CYP1B1 to give a metabolite which has been identified as the known antileukaemic agent piceatannol. The metabolite was identified by high performance liquid chromatography analysis using fluorescence detection and the identity of the metabolite was further confirmed by derivatisation followed by gas chromatography-mass spectrometry studies using authentic piceatannol for comparison. This observation provides a novel explanation for the cancer preventative properties of resveratrol. It demonstrates that a natural dietary cancer preventative agent can be converted to a compound with known anticancer activity by an enzyme that is found in human tumours. Importantly this result gives insight into the functional role of CYP1B1 and provides evidence for the concept that CYP1B1 in tumours may be functioning as a growth suppressor enzyme.


Subject(s)
Antineoplastic Agents, Phytogenic/metabolism , Antineoplastic Agents/chemistry , Aryl Hydrocarbon Hydroxylases , Cytochrome P-450 Enzyme System/metabolism , Stilbenes/chemistry , Stilbenes/metabolism , Antineoplastic Agents, Phytogenic/pharmacology , Chemoprevention , Chromatography, High Pressure Liquid , Cytochrome P-450 CYP1B1 , Gas Chromatography-Mass Spectrometry , Humans , Neoplasms/enzymology , Neoplasms/prevention & control , Resveratrol , Stilbenes/pharmacology , Tumor Cells, Cultured , Wine
4.
Arch Gen Psychiatry ; 58(12): 1172-6, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11735847

ABSTRACT

BACKGROUND: Numerous case reports have linked clozapine to the development of diabetes mellitus and hyperlipidemia in patients with schizophrenia. However, investigators have been unable to clearly demonstrate this association when compared with a control group receiving conventional antipsychotics. METHODS: Medical and pharmacy claims from the Iowa Medicaid program were used to compare incidence rates for diabetes, hyperlipidemia, and hypertension in 552 patients receiving clozapine and 2461 patients receiving conventional antipsychotics (eg, haloperidol, chlorpromazine hydrochloride), with the use of a retrospective cohort design. Logistic regression was used to compare incidence rates adjusting for age, sex, and duration of available follow-up. RESULTS: No significant differences in overall incidence rates for diabetes, hyperlipidemia, or hypertension were observed in patients receiving clozapine vs conventional antipsychotics. However, among younger patients (aged 20-34 years), clozapine administration was associated with a significantly increased relative risk of diabetes (2.5 [95% confidence interval, 1.2-5.4]) and hyperlipidemia (2.4 [95% confidence interval, 1.1-5.2]), but not hypertension (0.9 [95% confidence interval, 0.4-2.0]). CONCLUSIONS: These data suggest that clozapine may not be an independent cause of diabetes or hyperlipidemia, but instead acts as an effect modifier in susceptible populations by increasing weight or affecting insulin secretion and resistance. This finding requires confirmation in other settings and patient populations and with the other atypical antipsychotics (risperidone, olanzapine, and quetiapine fumarate). The potential long-term medical and economic implications of the early induction of diabetes and hyperlipidemia in patients with schizophrenia warrant further study.


Subject(s)
Antipsychotic Agents/adverse effects , Clozapine/adverse effects , Diabetes Mellitus, Type 2/chemically induced , Hyperlipidemias/chemically induced , Hypertension/chemically induced , Schizophrenia/drug therapy , Adult , Age Factors , Antipsychotic Agents/therapeutic use , Causality , Clozapine/therapeutic use , Cohort Studies , Confidence Intervals , Cross-Sectional Studies , Diabetes Mellitus, Type 2/diagnosis , Diabetes Mellitus, Type 2/epidemiology , Female , Follow-Up Studies , Humans , Hyperlipidemias/diagnosis , Hyperlipidemias/epidemiology , Hypertension/diagnosis , Hypertension/epidemiology , Incidence , Iowa , Male , Middle Aged , Product Surveillance, Postmarketing , Retrospective Studies , Risk , Schizophrenia/diagnosis , Schizophrenia/epidemiology
5.
Pharmacotherapy ; 21(8): 1003-6, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11718487

ABSTRACT

Neuroleptic malignant syndrome (NMS) is an uncommon but potentially life-threatening adverse effect associated with conventional antipsychotic agents. The syndrome is characterized by muscular rigidity, hyperpyrexia, altered consciousness, and autonomic dysfunction. Few cases of quetiapine-induced NMS have been reported. A 54-year-old man was unsuccessfully challenged with quetiapine after conventional antipsychotic-induced NMS.


Subject(s)
Antipsychotic Agents/adverse effects , Dibenzothiazepines/adverse effects , Neuroleptic Malignant Syndrome/etiology , Alzheimer Disease/complications , Antipsychotic Agents/administration & dosage , Chlorpromazine/adverse effects , Dibenzothiazepines/administration & dosage , Haloperidol/adverse effects , Humans , Hyperthyroidism/complications , Lorazepam/adverse effects , Male , Middle Aged , Neuroleptic Malignant Syndrome/diagnosis , Neuroleptic Malignant Syndrome/physiopathology , Psychomotor Agitation/complications , Psychomotor Agitation/drug therapy , Quetiapine Fumarate
6.
Ann Clin Psychiatry ; 13(2): 75-80, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11534928

ABSTRACT

Andropause is a syndrome described in aging males, is composed of a constellation of physical, sexual, and emotional symptoms, and is thought to be related to declining concentrations of serum testosterone. Numerous studies of testosterone replacement therapy in elderly hypogonadal males have documented the physical benefits of such treatment, but have failed to assess cognition, psychological functioning, and quality of life. Male outpatients greater or equal to 55 years of age completed cognitive, psychological, sexual, and quality of life assessments. A serum sample was provided for bioavailable testosterone assay. The associations between bioavailable testosterone concentrations and neuropsychological testing were assessed using Spearman rank correlation. Overall, bioavailable testosterone was not an important determinant of cognitive, psychological, or sexual functioning or of quality of life. The implications for future studies involving testosterone replacement therapy are discussed.


Subject(s)
Cognition/drug effects , Hypogonadism/drug therapy , Quality of Life , Sexual Behavior/psychology , Testosterone/pharmacology , Testosterone/therapeutic use , Aged , Aging/physiology , Biological Availability , Humans , Middle Aged
8.
Pharmacotherapy ; 21(6): 717-30, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11401184

ABSTRACT

Although the introduction of antipsychotic drugs in 1954 was a breakthrough in the treatment of patients with schizophrenia, these agents have a number of adverse effects that limit effectiveness and compliance. The atypical antipsychotic drugs provide an improved tolerability profile, particularly in minimizing extrapyramidal side effects; however, they are associated with significant weight gain, which may be related to growing evidence linking the atypical agents with diabetes and hyperlipidemia. Ziprasidone, a new atypical antipsychotic drug, was demonstrated in clinical trials to be more efficacious than placebo and similar in efficacy to haloperidol in the treatment of schizophrenia. Like the existing atypical agents, ziprasidone has a rate of extrapyramidal side effects similar to that of placebo and does not cause significant elevations in prolactin levels. In contrast, ziprasidone has a low propensity for causing weight gain. For patients requiring an antipsychotic drug, ziprasidone represents a new treatment option with a limited adverse effect profile.


Subject(s)
Antipsychotic Agents/therapeutic use , Bipolar Disorder/drug therapy , Piperazines/therapeutic use , Schizophrenia/drug therapy , Thiazoles/therapeutic use , Tourette Syndrome/drug therapy , Antipsychotic Agents/adverse effects , Antipsychotic Agents/pharmacokinetics , Clinical Trials as Topic , Drug Interactions , Humans , Piperazines/adverse effects , Piperazines/pharmacokinetics , Psychotic Disorders/drug therapy , Thiazoles/adverse effects , Thiazoles/pharmacokinetics
9.
J Clin Psychopharmacol ; 21(1): 14-20, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11199942

ABSTRACT

Olanzapine is an atypical antipsychotic that is effective in the treatment of schizophrenia. Olanzapine plasma concentrations > or = 9.3 ng/mL (24 hours postdose) have been identified as a predictor of clinical response in acutely ill patients with schizophrenia. The authors report a receiver operating characteristic (ROC) curve analysis of 12-hour olanzapine concentrations and treatment response from the North American Double-Blind Olanzapine Trial. After a 4- to 7-day placebo lead-in, patients meeting DSM-III-R criteria for schizophrenia were randomly assigned to receive olanzapine, haloperidol, or placebo. Patients who were randomly assigned to receive olanzapine were given daily doses ranging from 2.5 to 17.5 mg/day for up to 6 weeks. Blood samples for the determination of olanzapine plasma concentrations were obtained between 10 and 16 hours (11.7 +/- 1.7 hours) after the last dose was administered. Therapeutic response data and olanzapine concentrations used for analysis were obtained from the endpoint visit for each patient if the patient had been receiving a fixed olanzapine dose for at least the last 2 weeks of the study. Plasma concentrations from previous visits were used if endpoint concentrations were invalid. Response was defined as a > or = 20% reduction in Brief Psychiatric Rating Scale (BPRS) scores and a Clinical Global Impression (CGI) Severity scale score of < or = 3 or a final BPRS score of < or = 35. The final ROC analysis included data from 84 patients and suggested an olanzapine concentration > or = 23.2 ng/mL to be a predictor of therapeutic response. Fifty-two percent of patients with 12-hour olanzapine concentrations > or = 23.2 ng/mL responded, whereas only 25% of patients with concentrations < 23.2 ng/mL responded. Furthermore, an olanzapine concentration > or = 23.2 ng/mL was a predictor of response in the Scale for the Assessment of Negative Symptoms (> or = 20% decrease and endpoint CGI < or = 3). Olanzapine concentrations were found to be a function of olanzapine dose (in milligrams per day) and gender such that prospective olanzapine dosing is feasible. A 12-hour olanzapine plasma concentration of > 23.2 ng/mL was a predictor of therapeutic response in acutely ill patients with schizophrenia. Males required a higher olanzapine dose to reach this threshold concentration than their female counterparts.


Subject(s)
Antipsychotic Agents/blood , Pirenzepine/analogs & derivatives , Pirenzepine/blood , Schizophrenia/drug therapy , Acute-Phase Reaction , Adolescent , Adult , Antipsychotic Agents/therapeutic use , Benzodiazepines , Female , Humans , Male , Middle Aged , North America , Olanzapine , Outcome Assessment, Health Care , Pirenzepine/therapeutic use , Schizophrenia/blood , Treatment Outcome
10.
Mini Rev Med Chem ; 1(1): 31-41, 2001 May.
Article in English | MEDLINE | ID: mdl-12369989

ABSTRACT

Four-stranded tetraplex ("G-quadruplex") DNA represents a new paradigm for the design of DNA-interactive antitumour drugs, as the formed DNA-drug complexes have been suggested to interfere with critical telomerase function. The unique structural features presented by tetraplex over duplex DNA have stimulated the design of small ligand molecules able to selectively promote the formation and/or stabilisation of such higher-order DNA structures. Current developments in tetraplex-targeted telomerase inhibitors, and importantly their DNA structural selectivity, are explored.


Subject(s)
Antineoplastic Agents/therapeutic use , DNA/chemistry , Enzyme Inhibitors/therapeutic use , Telomerase/antagonists & inhibitors , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Cell Line , Cell Survival/drug effects , DNA/drug effects , Drug Design , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacology , Humans , Ligands , Structure-Activity Relationship
11.
Psychopharmacol Bull ; 35(3): 19-29, 2001.
Article in English | MEDLINE | ID: mdl-12397876

ABSTRACT

Therapeutic drug monitoring of conventional and atypical antipsychotics offers numerous clinical advantages to the clinician. These include cost savings, decreased risk of toxicity, and improved compliance. Among these drugs, studies of haloperidol, olanzapine, and clozapine have provided the most compelling data to justify therapeutic drug monitoring. Among atypical antipsychotics, although data document the utility of routine monitoring of clozapine and olanzapine blood levels, there are no similar data available for either risperidone or quetiapine. Additionally, the utility of therapeutic drug monitoring is enhanced by the availability of prospective dosing schemes for haloperidol, olanzapine, and clozapine.


Subject(s)
Antipsychotic Agents/therapeutic use , Drug Monitoring , Psychotic Disorders/drug therapy , Animals , Antipsychotic Agents/administration & dosage , Humans
12.
Expert Opin Investig Drugs ; 10(12): 2141-56, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11772310

ABSTRACT

Telomerase is a holoenzyme responsible for the maintenance of telomeres, the protein-nucleic acid complexes at the ends of eukaryotic chromosomes that serve to maintain chromosomal stability and integrity. Telomerase activity is essential for the sustained proliferation of most immortal cells, including cancer cells. Since the discovery that telomerase activity is detected in 85-90% of all human tumours and tumour-derived cell lines but not in most normal somatic cells, telomerase has become the focus of much attention as a novel and potentially highly-specific target for the development of new anticancer chemotherapeutics. Herein we review the current perspective for the development of telomerase inhibitors as cancer chemotherapeutics. These include antisense strategies, reverse transcriptase inhibitors and compounds capable of interacting with high-order telomeric DNA tetraplex ("G-quadruplex") structures, so as to prevent enzyme access to the necessary linear telomere substrate. Critical appraisal of each individual approach is provided together with highlighted areas of likely future development.


Subject(s)
Antineoplastic Agents/therapeutic use , Enzyme Inhibitors/therapeutic use , Neoplasms/drug therapy , Telomerase/antagonists & inhibitors , Animals , Clinical Trials as Topic , Humans , Telomere/drug effects
13.
Ann Clin Psychiatry ; 13(3): 129-34, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11791949

ABSTRACT

Despite the increasing recognition of attention-deficit hyperactivity disorder (ADHD) in adults, there are few controlled trials demonstrating the effectiveness of pharmacological treatments, particularly with nonstimulants. One controlled trial found bupropion SR more effective than placebo in the treatment of ADHD adults. We conducted a controlled study to contrast the effectiveness of bupropion SR and methylphenidate to placebo in ADHD adults. A randomized, double-blind, parallel design was used in this study. Following a 7-day placebo lead-in, 30 ADHD (DSM-IV) subjects (18-60 years old) were randomized to bupropion, methylphenidate, or placebo for 7 weeks. Methylphenidate was titrated over 1 week to a maximum dose of 0.9 mg/kg/d divided into 3 doses while bupropion was titrated over 2 weeks to a maximum dose of 200 mg A.M. and 100 mg P.M. Response rates based on Clinical Global Impression improvement ratings in patients receiving bupropion, methylphenidate, and placebo were 64, 50, and 27%, respectively. The difference in response rates between active treatment and placebo was not statistically significant (p = 0.14). Neuropsychological testing demonstrated trends favoring drug treatment on measures of immediate recall and verbal fluency. While bupropion SR may be a viable clinical alternative for adults with ADHD, further investigation is needed.


Subject(s)
Adrenergic Agents/therapeutic use , Attention Deficit Disorder with Hyperactivity/drug therapy , Bupropion/therapeutic use , Dopamine Uptake Inhibitors/therapeutic use , Methylphenidate/therapeutic use , Adult , Attention Deficit Disorder with Hyperactivity/psychology , Double-Blind Method , Female , Humans , Male , Neuropsychological Tests , Severity of Illness Index , Time Factors , Treatment Outcome
14.
Pharmacotherapy ; 20(7): 844-7, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10907975

ABSTRACT

Clozapine is an atypical antipsychotic that is associated with certain adverse effects that limit its usefulness. Published case reports have associated clozapine with impairment of glucose tolerance, including the onset or exacerbation of diabetes mellitus. We report two patients who experienced diabetes mellitus associated with the agent.


Subject(s)
Antipsychotic Agents/adverse effects , Clozapine/adverse effects , Diabetes Mellitus/chemically induced , Antipsychotic Agents/therapeutic use , Chronic Disease , Clozapine/therapeutic use , Female , Glucose Tolerance Test , Humans , Middle Aged , Schizophrenia/complications , Schizophrenia/drug therapy
15.
Clin Endocrinol (Oxf) ; 52(6): 781-7, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10848884

ABSTRACT

OBJECTIVE: Limited data are available on the effects of the menstrual cycle on the hypothalamic-pituitary-adrenal axis (HPA) function. This study evaluates HPA axis reactivity to insulin-induced hypoglycaemia over the menstrual cycle. PATIENTS: Twelve normal women were randomized to placebo and evaluated during three successive menstrual cycles. Menstrual phase was documented by menstrual diary and by oestradiol and progesterone levels at the time of each insulin tolerance test (ITT). Six normal men were included as a comparison in the statistical analysis. MEASUREMENTS: Afternoon ITTs were performed initially on the second or third day of menses in women, then seven more ITTs followed at one or two week intervals during the next 10 weeks. Serum measurements of glucose, adrenocorticotrophin (ACTH) and cortisol were obtained. RESULTS: The glucose and ACTH responses to the ITTs were similar between men and women. Cortisol levels at baseline and during the test were higher in men than in women, although the amount of change was similar. Glucose, ACTH and cortisol response to insulin-induced hypoglycaemia did not vary over the menstrual cycle or during repeat testing in men or women. CONCLUSIONS: These data show that it is unnecessary to control for menstrual cycle during insulin tolerance tests performed at 1600 hours. It is, however, necessary to control for the effect of sex on cortisol levels. Repeat testing more than one week apart does not appear to influence the glucose, ACTH or cortisol response to insulin stress.


Subject(s)
Hypoglycemia/physiopathology , Hypoglycemic Agents , Hypothalamo-Hypophyseal System/physiopathology , Insulin , Menstruation/physiology , Pituitary-Adrenal System/physiopathology , Adrenocorticotropic Hormone/blood , Adult , Analysis of Variance , Female , Humans , Hydrocortisone/blood , Male , Middle Aged
17.
Expert Opin Pharmacother ; 1(2): 305-23, 2000 Jan.
Article in English | MEDLINE | ID: mdl-11249551

ABSTRACT

Olanzapine is a serotonin-dopamine receptor antagonist primarily used in the treatment of psychotic illnesses. It has been shown in numerous large trials to be as equally effective as haloperidol in the acute treatment and maintenance treatment of schizophrenia. However, olanzapine was shown to be more effective than haloperidol in the treatment of negative symptoms and to cause significantly fewer extrapyramidal symptoms. Furthermore, early reports suggest that olanzapine produces less tardive dyskinesia than haloperidol, though longer follow-up data are needed. Current studies have failed to demonstrate the efficacy of olanzapine in the treatment of refractory schizophrenia. One comparison trial of olanzapine versus risperidone has indicated similar efficacy. Clinical trials in acute mania have found olanzapine to be more effective than placebo. However, there is no role for olanzapine monotherapy in bipolar disorder given current studies. Although olanzapine has shown a low rate of extrapyramidal symptoms, it is not without adverse effects. Clinically significant weight gain has been noted with olanzapine in each of the large clinical trials. The degree of weight gain is similar to clozapine and probably greater than that observed with risperidone. The long-term medical consequence of atypical antipsychotic-induced weight gain is not known at this time. While generally considered first-line drugs from an efficacy and adverse effect standpoint, pharmacoeconomic studies are needed to justify the large acquisition cost of olanzapine compared to typical agents.


Subject(s)
Antipsychotic Agents/therapeutic use , Pirenzepine/analogs & derivatives , Pirenzepine/therapeutic use , Schizophrenia/drug therapy , Antipsychotic Agents/adverse effects , Antipsychotic Agents/economics , Antipsychotic Agents/pharmacokinetics , Antipsychotic Agents/pharmacology , Benzodiazepines , Clinical Trials as Topic , Humans , Olanzapine , Pirenzepine/adverse effects , Pirenzepine/economics , Pirenzepine/pharmacokinetics , Pirenzepine/pharmacology , Schizophrenia/complications , Schizophrenia/economics , Schizophrenic Psychology
18.
Pharmacotherapy ; 19(12): 1437-8, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10600093

ABSTRACT

Pergolide is a dopaminergic agonist used to treat Parkinson's disease but is associated with the development of retroperitoneal fibrosis (RPF). Newer nonergot agents (pramipexole, ropinirole) may not carry this same risk. A patient with a history of pergolide-induced RPF was treated successfully with ropinirole for 1 year without complications.


Subject(s)
Antiparkinson Agents/therapeutic use , Indoles/therapeutic use , Parkinson Disease/drug therapy , Pergolide/adverse effects , Retroperitoneal Fibrosis/chemically induced , Aged , Aged, 80 and over , Antiparkinson Agents/adverse effects , Female , Humans , Pergolide/therapeutic use
19.
Eur J Biochem ; 263(3): 817-25, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10469146

ABSTRACT

We have used quantitative DNase I footprinting to measure the relative affinities of four disubstituted and two monosubstituted amidoanthraquinone compounds for intermolecular DNA triplexes, and have examined how the position of the attached base-functionalized substituents affects their ability to stabilize DNA triplexes. All four isomeric disubstituted derivatives examined stabilize DNA triplexes at micromolar or lower concentrations. Of the compounds studied the 2,7-disubstituted amidoanthraquinone displayed the greatest triplex affinity. The order of triplex affinity for the other disubstituted ligands decreases in the order 2,7 > 1,8 = 1,5 > 2,6, with the equivalent monosubstituted compounds being at least an order of magnitude less efficient. The 1,5-disubstituted derivative also shows some interaction with duplex DNA. These results have been confirmed by molecular modelling studies, which provide a rational basis for the structure-activity relationships. These suggest that, although all of the compounds bind through an intercalative mode, the 2,6, 2,7 and 1,5 disubstituted isomers bind with their two side groups occupying adjacent triplex grooves, in contrast with the 1,8 isomer which is positioned with both side groups in the same triplex groove.


Subject(s)
Amides/pharmacology , Anthraquinones/pharmacology , DNA/chemistry , Nucleic Acid Conformation , Oligodeoxyribonucleotides/chemistry , Amides/chemistry , Anthraquinones/chemistry , Base Sequence , Calorimetry , Computer Graphics , DNA/drug effects , DNA Footprinting , Deoxyribonuclease I , Macromolecular Substances , Models, Molecular , Molecular Sequence Data , Nucleic Acid Conformation/drug effects , Structure-Activity Relationship
20.
Pharmacotherapy ; 19(8): 951-6, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10453966

ABSTRACT

Andropause, a syndrome in aging men, consists of physical, sexual, and psychologic symptoms that include weakness, fatigue, reduced muscle and bone mass, impaired hematopoiesis, oligospermia, sexual dysfunction, depression, anxiety, irritability, insomnia, memory impairment, and reduced cognitive function. Free testosterone levels begin to decline at a rate of 1% per year after age 40 years. It is estimated that 20% of men aged 60-80 years have levels below the lower limit of normal. Although the causal relationship between declining testosterone levels and development of andropause symptoms is not firmly established, administration of testosterone to this population resulted in improvements in many areas. Most studies to date focused on physical benefits of testosterone replacement and failed to assess psychologic symptoms rigorously. Preliminary data suggest that therapy may benefit elderly men with new-onset depression. Testosterone administration is not without problems, the most worrisome being the potential for increased prostate cancer risk. Despite this concern, a limited number of studies administered the hormone weekly for up to 2 years, with only mild increases in prostate-specific antigen over control values. Currently, insufficient evidence, primarily regarding psychologic safety and efficacy, exists to warrant general administration of testosterone to elderly hypogonadal men. Further clinical investigations of this therapy in men with low testosterone levels and andropause symptoms are justified and necessary.


Subject(s)
Hormone Replacement Therapy/methods , Testosterone/therapeutic use , Aged , Hormone Replacement Therapy/adverse effects , Hormone Replacement Therapy/psychology , Humans , Male , Middle Aged , Prostatic Neoplasms/chemically induced , Testosterone/adverse effects , Testosterone/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...